Martínez-Ortega Jesús Iván, Ramirez Cibrian Arely Gissell, Martinez-Jaramillo Elvis, García Silva Maria Del Consuelo
Dermatology, Dermatological Institute of Jalisco, "Dr. José Barba Rubio", Guadalajara, MEX.
Medical Benefits, Mexican Institute of Social Security, Campeche, MEX.
Cureus. 2024 Feb 9;16(2):e53925. doi: 10.7759/cureus.53925. eCollection 2024 Feb.
In this case report, we present a distinctive occurrence of classic Kaposi sarcoma (KS) in an individual of Latin origin, emerging seven days following the administration of the third dose of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine. The progression of KS continued over two months, culminating in the development of a tumor. Given the absence of prior reports on KS development post-COVID-19 vaccination, the primary aim of this report is to explore the potential relationship between the ChAdOx1 nCoV-19 vaccine, reactivation of Kaposi sarcoma-associated herpes virus, and the subsequent onset of KS.
在本病例报告中，我们呈现了一例独特的经典卡波西肉瘤（KS）病例，患者为拉丁裔，在接种第三剂ChAdOx1 nCoV-19（阿斯利康）疫苗七天后发病。KS的病程持续了两个月，最终发展成肿瘤。鉴于此前尚无COVID-19疫苗接种后发生KS的报告，本报告的主要目的是探讨ChAdOx1 nCoV-19疫苗、卡波西肉瘤相关疱疹病毒的重新激活与随后KS发病之间的潜在关系。
